Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor or a nitric oxide inhibitor

US5948762A · kind A · utility

Assignees

• SCHERING CORPORATION · US
• UNIVERSITY OF TEXAS SYSTEM · US

Inventors

• Robert E. Garfield · Goodyear, US
• Krzysztof Chwalisz · Berlin, DE
• Radoslaw Bukowski · Berlin, DE
• Chandra Yallampalli · Houston, US

Key dates

• Filing date: Jul 17, 1997
• Grant date: Sep 7, 1999
• Expiry date: Jul 17, 2017

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/095
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Dysmenorrhea, disfunctional uterine bleeding, preterm labor and postpartum labor in female mammals are treated by inhibiting uterine contractility by administering thereto a nitric oxide synthase substrate, a nitric oxide donor or both, optionally in combination with one or more of a prostaglandin inhibitor, a prostacyclin-mimetic, a progestin, an oxytocin antagonist or a .beta.-agonist in an amount effective to ameliorate the symptoms thereof; and inadequate menses treated and induction of abortion or stimulation of labor in a pregnant female is achieved by uterine contractility stimulation by administering thereto a nitric oxide inhibitor, either alone or optionally in a combination of progesterone antagonist, an oxytocin or-oxytocin analogue antagonist or a prostaglandin.